732
Participants
Start Date
May 21, 2009
Primary Completion Date
April 17, 2012
Study Completion Date
May 23, 2018
Sorafenib (Nexavar, BAY43-9006)
Sorafenib 400 mg twice daily
Erlotinib (Tarceva)
Erlotinib 150 mg once daily
Placebo
Matching erlotinib placebo 150 mg once daily
Taipei
Taoyuan District
Tainan City
Auckland
Vienna
Bruxelles - Brussel
Sofia
Randwick
Johannesburg
Edegem
Leuven
Melbourne
Clayton
Liège
Plovdiv
Herston
Brisbane
Nedlands
Wellington South
La Louvière
Cape Town
Christchurch
Kortrijk
Ghent
Varna
Varna
New York
Valhalla
Berlin
Marseille
Rochester
Philadelphia
Washington D.C.
Milan
Baltimore
Lugo
Madrid
Charlotte
Atlanta
Hanover
Gainesville
Bordeaux
Miami
Pessac
Santander
Louisville
Larissa
Essen
Valencia
Valencia
Detroit
Cologne
Vandœuvre-lès-Nancy
Thessaloniki
Mainz
Minneapolis
Lille
Frankfurt am Main
Westwood
Homburg
Lyon
New Orleans
Zrifin
Tübingen
Paris
Houston
Freiburg im Breisgau
München
La Roche-sur-Yon
Clichy
Regensburg
Créteil
San Francisco
Villejuif
Honolulu
Beijing
Beijing
Moscow
Singapore
Nanjing
Singapore
Hangzhou
Guangzhou
Nizhny Novgorod
Barnaul
Haifa
Petah Tikva
Santiago
Rehovot
Beersheba
Maywood
Boston
Boston
Worcester
Seattle
Belo Horizonte
Porto Alegre
São Paulo
Rio de Janeiro
São Paulo
São Paulo
Edmonton
Montreal
Santiago
Floridablanca
Medellín
Hong Kong
Shatin
Athens
Thessaloniki
Lima
Lima
Bydgoszcz
Gdansk
Gliwice
Warsaw
Goyang-si
Seoul
Seoul
Seoul
Seoul
L'Hospitalet de Llobregat
Barcelona
Sheffield
Glasgow
London
Newcastle upon Tyne
Lead Sponsor
Bayer
INDUSTRY